Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Positive news lifts Dr.Reddy's
Wed, 6 Jan 01:30 pm

The Indian stock markets continue to remain volatile after a strong start. Healthcare and realty were leading the market while IT and telecom were trading under the dotted line on account of profit booking.

The BSE Sensex and NSE Nifty were trading in the green, albeit marginally higher. BSE Sensex was higher by 15 points while NSE Nifty was higher by 3 points. The BSE Midcap index was trading higher by 46 points while the BSE Smallcap index was trading up by 60 points. The rupee is trading at 46.15 to the dollar.

As per a leading daily, Ashok Leyland has indicated that it will hike the price of its commercial vehicles shortly. The company has cited rising steel prices, change in technology due to new emission norms and fixed price contracts with local transport bodies as some of the reasons for this hike. The quantum of this hike is expected to be around 2 - 3% across categories and is expected to happen around March. Ashok Leyland has witnessed good sales numbers in the last 2 quarters and expects to close the year with total sale of 62,000 - 63,000 units. The company expects good growth going forward despite this hike and is aiming for a double digit growth next fiscal.

Dr. Reddy was up by 3.3% at the time of writing this report. The company has pulled a first for an Indian company. Indian drug industry’s dream of coming out with its own new chemical entity (NCE) or an originally researched drug received a boost with Balaglitazone showing encouraging results in the first leg of human trials. This is an anti-diabetic drug being developed by Dr. Reddy jointly with Denmark-based Rheoscience. The companies intend to present their findings to regulators in developed markets and will take a call based on their feedback on their course of further action. Phase 3 trials are expensive as a large number of patients are involved in this. Since there is a chance of failure even at this stage, investors are advised to exercise caution.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Positive news lifts Dr.Reddy's". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.